Hepatitis C New Drugs Review
26.7K views | +4 today
Follow
 
Scooped by Krishan Maggon
onto Hepatitis C New Drugs Review
Scoop.it!

WHO | Hepatitis treatment debuts on WHO Model Essential Medicines List

Good news has emerged for the 150 million people worldwide who have hepatitis C – a lifelong condition that is transmitted through contact with the blood of an infected person and can lead to cirrhosis, liver cancer, and even death.
more...
No comment yet.
Hepatitis C New Drugs Review
FDA approved Incivek(telaprevir, Vertex) on Monday 23 May by its PDUFA deadline.A paradigm shift in the treatment of Hepatitis C virus infection. http://knol.google.com/k/krishan-maggon/boceprevir-merck-telaprevir-vertex/3fy5eowy8suq3/151#
Curated by Krishan Maggon
Your new post is loading...
Your new post is loading...
Scooped by Krishan Maggon
Scoop.it!

Created public version #121 of the knol: "Boceprevir (Merck) & Telaprevir (Vertex) Hepatitis C : FDA Review & Approval"

Created public version #121 of the knol: "Boceprevir (Merck) & Telaprevir (Vertex) Hepatitis C : FDA Review & Approval" | Hepatitis C New Drugs Review | Scoop.it
Krishan Maggon published version 121 of a knol titled: "Boceprevir (Merck) & Telaprevir (Vertex) Hepatitis C : FDA Review & Approval"...
more...
Scooped by Krishan Maggon
Scoop.it!

Hepatitis therapy: Kupffer cells adjust the balance between pathogen control and hepatocyte regeneration

Hepatitis therapy: Kupffer cells adjust the balance between pathogen control and hepatocyte regeneration | Hepatitis C New Drugs Review | Scoop.it
Empty description
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Ultra-Deep Genomic Sequencing of HCV NS5A Resistance-Associated Substitutions in HCV/HIV Coinfected Patients

Ultra-Deep Genomic Sequencing of HCV NS5A Resistance-Associated Substitutions in HCV/HIV Coinfected Patients | Hepatitis C New Drugs Review | Scoop.it
The prevalence of naturally occurring HCV-NS5A resistance-associated substitutions (RAS) to DAA drugs might affect the response to treatment in HCV/HIV coinfected subjects. There are limited data on t
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis

Hepatitis C virus (HCV) has high genotypic diversity and global distribution. Agents
that are effective against all major HCV genotypes, with shorter treatment duration,
are needed to reduce disease burden. Glecaprevir (an NS3/4A protease inhibitor) and
pibrentasvir (an NS5A inhibitor) have a high barrier to resistance and synergistic
antiviral activity. We evaluated the safety and efficacy of 8 and 12 weeks’ treatment
with glecaprevir/pibrentasvir in patients with HCV genotype 2, 4, 5, or 6 infection
without cirrhosis in 3 separate phase 3 trials.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Effect of Shorter Treatment Regimens for Hepatitis C on Population Health and Under Fixed Budgets | Open Forum Infectious Diseases | Oxford Academic

Effect of Shorter Treatment Regimens for Hepatitis C on Population Health and Under Fixed Budgets | Open Forum Infectious Diseases | Oxford Academic | Hepatitis C New Drugs Review | Scoop.it
AbstractBackground. Direct acting antiviral hepatitis C virus (HCV) therapies are highly effective but costly. Wider adoption of an 8-week ledipasvir/sofosbuvi
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Neutrons reveal hidden secrets of the hepatitis C virus

Neutrons reveal hidden secrets of the hepatitis C virus | Hepatitis C New Drugs Review | Scoop.it
The hepatitis C virus (HCV) is a blood born virus that causes liver disease and cancer, with more than 300,000 people dying each year and 71 million people living with a chronic infection worldwide . While antiviral medicine
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

[1801.04587] A Bayesian Evidence Synthesis Approach to Estimate Disease Prevalence in Hard-To-Reach Populations: Hepatitis C in New York City

[1801.04587] A Bayesian Evidence Synthesis Approach to Estimate Disease Prevalence in Hard-To-Reach Populations: Hepatitis C in New York City | Hepatitis C New Drugs Review | Scoop.it
Download: PDF only (license) Current browse context: stat.AP < prev | next > new | recent | 1801 Change to browse by: stat References & Citations NASA ADS Statistics > Applications A Bayesian Evidence Synthesis Approach to Estimate Disease Prevalence in Hard-To-Reach Populations: Hepatitis C in...
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Hepatitis C Treatment | Advances in Medication | ALF

Hepatitis C Treatment | Advances in Medication | ALF | Hepatitis C New Drugs Review | Scoop.it

Recent advances in the number and types of medications available to treat Hepatitis C give you and your doctor more options to consider when deciding on a treatment plan. These advances have made treatment regimens shorter in duration, less difficult to tolerate and more effective. What follows is a general outline of the main indications for each drug approved by the U.S. Food and Drug Administration (FDA) to treat Hepatitis C. The drugs are listed in chronological order by date of approval, allowing you to see the advances in medications used to treat HCV infection.

more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Remission of Psoriasis After Treatment of Chronic Hepatitis C Virus Infection With Direct-Acting Antivirals | Annals of Internal Medicine | American College of Physicians

Remission of Psoriasis After Treatment of Chronic Hepatitis C Virus Infection With Direct-Acting Antivirals | Annals of Internal Medicine | American College of Physicians | Hepatitis C New Drugs Review | Scoop.it

Background: Hepatitis C virus (HCV) infection is a systemic disease with extrahepatic manifestations that include skin involvement, such as mixed cryoglobulinemia, lichen planus, and porphyria cutanea tarda (1).


Case Report: In September 2015, an 80-year-old man with a 9-year history of refractory psoriasis was referred to us. The patient had small, well-demarcated, pruritic, scaly erythema on the trunk and upper and lower extremities with a Psoriasis Area and Severity Index score of 8.3 (Figure 1, left). We continued topical therapy with the corticosteroid clobetasol and the vitamin D3 analogue maxacalcitol and added narrowband ultraviolet B phototherapy, 0.5 J/cm2 weekly (Figure 2). The patient's symptoms and signs persisted even after topical therapy was replaced with betamethasone and the vitamin D3 analogue calcipotriol.

more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Analysis of Plasma Tenascin-C in Post-HCV Cirrhosis: A Prospective Study

Analysis of Plasma Tenascin-C in Post-HCV Cirrhosis: A Prospective Study | Hepatitis C New Drugs Review | Scoop.it
Hepatitis C virus (HCV)-related cirrhosis, one of the most common etiologies of liver cirrhosis in the Western world, is a risk factor for hepatocellular carcinoma. To confirm and improve current effe
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Co-existing Hepatitis C and Alcoholic Liver Disease: A Diminishing Indication for Liver Transplantation? | Alcohol and Alcoholism | Oxford Academic

Co-existing Hepatitis C and Alcoholic Liver Disease: A Diminishing Indication for Liver Transplantation? | Alcohol and Alcoholism | Oxford Academic | Hepatitis C New Drugs Review | Scoop.it
AbstractAims. To provide an overview of published literature on the interaction of alcohol and hepatitis C virus (HCV) in the accelerated progression of liver
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

New Year, New Gilead? It’s No Longer Just About Hepatitis C

New Year, New Gilead? It’s No Longer Just About Hepatitis C | Hepatitis C New Drugs Review | Scoop.it
Gilead's drug launches beyond Hepatitis C could make investors more interested in the stock.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Non-coding RNAs in hepatocellular carcinoma: molecular functions and pathological implications

Non-coding RNAs in hepatocellular carcinoma: molecular functions and pathological implications | Hepatitis C New Drugs Review | Scoop.it

Review


In this Review, we summarize the common deregulation of small and long ncRNAs in human HCC. We also comprehensively review the pathological roles of ncRNAs in liver carcinogenesis, epithelial-to-mesenchymal transition and HCC metastasis and discuss the potential applications of ncRNAs as diagnostic tools and therapeutic targets in human HCC.

more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial

Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial | Hepatitis C New Drugs Review | Scoop.it
Our results show that 99% of patients treated with once-daily glecaprevir plus pibrentasvir
achieved a sustained virological response at 12 weeks. Furthermore, this drug regimen
had a favourable safety profile in previously treated or untreated patients with chronic
HCV genotype 1, 2, 4, 5, or 6 infection and compensated cirrhosis. These findings
could help simplify treatment algorithms and reduce treatment burden.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Risk of Hepatitis B Virus Reactivation Among Patients Treated With Ledipasvir-Sofosbuvir for Hepatitis C Virus Infection

Risk of Hepatitis B Virus Reactivation Among Patients Treated With Ledipasvir-Sofosbuvir for Hepatitis C Virus Infection | Hepatitis C New Drugs Review | Scoop.it
Direct acting antiviral (DAA) agents are the standard of care for treatment of hepatitis C virus (HCV)–infected individuals. Hepatitis B virus (HBV) reactivation during HCV treatment has been reported, the incidence and clinical outcome remains unclear. The aim of our study is to examine the ris
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Identifying pre-existing NS3 and NS5A resistance-associated variants and transmission chains in the Polish HIV/HCV genotype 1 epidemic: impact on prevention and treatment

Identifying pre-existing NS3 and NS5A resistance-associated variants and transmission chains in the Polish HIV/HCV genotype 1 epidemic:  impact on prevention and treatment | Hepatitis C New Drugs Review | Scoop.it
Hepatitis C virus (HCV) resistance-associated variants (RAVs) have been shown to adversely affect treatment response of direct-acting antivirals (DAAs). Identifying pre-existing RAVs and transmission networks among HIV/HCV genotype 1 (G1) infected patients from Poland will assist in shapin
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Authentic Patient-Derived Hepatitis C Virus Infects and Productively Replicates in Primary CD4+ and CD8+ T Lymphocytes In Vitro

Authentic Patient-Derived Hepatitis C Virus Infects and Productively Replicates in Primary CD4+ and CD8+ T Lymphocytes In Vitro | Hepatitis C New Drugs Review | Scoop.it
Authentic Patient-Derived Hepatitis C Virus Infects and Productively Replicates in Primary CD4+ and CD8+ T Lymphocytes In Vitro Georgia Skardasia, Annie Y. Chena and Tomasz I. Michalaka aMolecular Virology and Hepatology Research Group, Division of BioMedical Sciences, Faculty of Medicine, Health...
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Extrahepatic cancers and chronic HCV infection

Extrahepatic cancers and chronic HCV infection | Hepatitis C New Drugs Review | Scoop.it

Review


 Abstract Infectious agents, such as HCV, account for ∼15% of human cancers. HCV infects not only hepatocytes but also extrahepatic cells. Chronic HCV infection can induce chronic inflammation with qualitative and quantitative alterations of the immune repertoire and tissue microenvironment, which could induce various neoplasias. Epidemiological studies and meta-analyses suggest an increased rate of extrahepatic cancers in patients with chronic HCV infection along with a higher risk of intrahepatic cholangiocarcinoma, pancreatic cancer and non-Hodgkin lymphoma (NHL), highlighting the need to screen for HCV infection in patients with these cancers. Development of B cell NHL has been associated with HCV infection, with a relative risk of ∼1.5. Direct transformation related to the presence of the virus and chronic antigenic stimulation are the two major non-exclusive mechanisms involved in HCV-related lymphomagenesis. HCV infection alters survival of patients with lymphoma, and sustained virologic response (SVR) substantially improves prognosis. Antiviral treatments might induce remission of indolent lymphoma when SVR is achieved even without chemotherapy, emphasizing the role of HCV in lymphomagenesis in this context. However, studies are needed to provide prospective evidence of a causal relationship between chronic HCV infection and other extrahepatic cancers and to determine whether the risk of extrahepatic cancers is reduced with SVR. In this Review, we report on recent studies analysing the risk of extrahepatic cancers associated with chronic HCV infection. Although there is no doubt regarding the direct and indirect causality between HCV and NHL, an increased risk of other cancers is less clear, with the exception of cholangiocarcinoma.

Krishan Maggon 's insight:
Extrahepatic cancers and chronic HCV infection 
Stanislas Pol, Anaïs Vallet-Pichard & Olivier Hermine 
Nature Reviews Gastroenterology & Hepatology doi:10.1038/nrgastro.2017.172 
Published online: 17 January 2018
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Oncotarget | Hepatocellular carcinoma cases with high levels of c-Raf-1 expression may benefit from postoperative adjuvant sorafenib after hepatic resection even with...

Oncotarget | Hepatocellular carcinoma cases with high levels of c-Raf-1 expression may benefit from postoperative adjuvant sorafenib after hepatic resection even with... | Hepatitis C New Drugs Review | Scoop.it
Hepatocellular carcinoma cases with high levels of c-Raf-1 expression may benefit from postoperative adjuvant sorafenib after hepatic resection even with high risk of recurrence
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

New Onset of Multi-Drug Hypersensitivity Reaction after Successful Treatment of Hepatitis C with Ledipasvir-Sofosbuvir in CKD: A Case Report.

New Onset of Multi-Drug Hypersensitivity Reaction after Successful Treatment of Hepatitis C with Ledipasvir-Sofosbuvir in CKD: A Case Report. | Hepatitis C New Drugs Review | Scoop.it
New Onset of Multi-Drug Hypersensitivity Reaction after Successful Treatment of Hepatitis C with Ledipasvir-Sofosbuvir in CKD: A Case Report., Alexander Myint Swan, Thein Aung, Zaw
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Characteristics of Inpatient Stays Involving Hepatitis C, 2005-2014 #232

Characteristics of Inpatient Stays Involving Hepatitis C, 2005-2014 #232 | Hepatitis C New Drugs Review | Scoop.it
Hepatitis C-related inpatient stays are presented among adults aged 18 years and older with and without key co-occurring diagnoses: hepatitis B, HIV, and alcoholic liver disease. Trends in the number and population rate of hepatitis C-related stays from 2005 through 2014 are provided. Characteristics of hepatitis C-related stays in 2014 are presented by patient age group—with a focus on baby boomers. Finally, the rate of hepatitis C-related stays in 2014 is depicted by U.S. census division for each patient age group.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Frontiers | Preclinical Development and Production of Virus-Like Particles As Vaccine Candidates for Hepatitis C | Microbiology

Frontiers | Preclinical Development and Production of Virus-Like Particles As Vaccine Candidates for Hepatitis C | Microbiology | Hepatitis C New Drugs Review | Scoop.it
Hepatitis C Virus (HCV) infects 2% of the world’s population and is the leading cause of liver disease and liver transplantation. It poses a serious and growing worldwide public health problem that will only be partially addressed with the introduction of new antiviral therapies. However, these treatments will not prevent re-infection particularly in high risk populations. The introduction of a HCV vaccine has been predicted, using simulation models in a high risk population, to have a significant effect on reducing the incidence of HCV. A vaccine with 50% to 80% efficacy targeted to high-risk intravenous drug users could dramatically reduce HCV incidence in this population. Virus like particles (VLPs) are composed of viral structural proteins which self-assemble into non-infectious particles that lack genetic material and resemble native viruses. Thus, VLPs represent a safe and highly immunogenic vaccine delivery platform able to induce potent adaptive immune responses. Currently, many VLP-based vaccines have entered clinical trials, while licensed VLP vaccines for hepatitis B virus (HBV) and human papilloma virus (HPV) have been in use for many years. The HCV core, E1 and E2 proteins can self-assemble into immunogenic VLPs while inclusion of HCV antigens into heterogenous (chimeric) VLPs is also a promising approach. These VLPs are produced using different expression systems such as bacterial, yeast, mammalian, plant, or insect cells. Here, this paper will review HCV VLP-based vaccines and their immunogenicity in animal models as well as the different expression systems used in their production.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Efficacy of Ledipasvir and Sofosbuvir Treatment of HCV Infection in Patients Coinfected with HBV

Efficacy of Ledipasvir and Sofosbuvir Treatment of HCV Infection in Patients Coinfected with HBV | Hepatitis C New Drugs Review | Scoop.it
There have been reports of reactivation of hepatitis B virus (HBV) infection during
treatment of hepatitis C virus (HCV) infection with direct-acting antiviral agents.
We performed a prospective study of risks and outcomes of HCV infection treatment
with ledipasvir and sofosbuvir in patients with HBV infection.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Differential Effects of Human Immunodeficiency Virus and Hepatitis C Virus on Bone Microarchitecture and Fracture Risk | Clinical Infectious Diseases | Oxford Academic

Differential Effects of Human Immunodeficiency Virus and Hepatitis C Virus on Bone Microarchitecture and Fracture Risk | Clinical Infectious Diseases | Oxford Academic | Hepatitis C New Drugs Review | Scoop.it
The mechanism(s) underlying the increased fracture risk associated with HIV and hepatitis C virus (HCV) infection are incompletely understood. We hereby show fo
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention

Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention | Hepatitis C New Drugs Review | Scoop.it

Review


Abstract NAFLD is one of the most important causes of liver disease worldwide and will probably emerge as the leading cause of end-stage liver disease in the coming decades, with the disease affecting both adults and children. The epidemiology and demographic characteristics of NAFLD vary worldwide, usually parallel to the prevalence of obesity, but a substantial proportion of patients are lean. The large number of patients with NAFLD with potential for progressive liver disease creates challenges for screening, as the diagnosis of NASH necessitates invasive liver biopsy. Furthermore, individuals with NAFLD have a high frequency of metabolic comorbidities and could place a growing strain on health-care systems from their need for management. While awaiting the development effective therapies, this disease warrants the attention of primary care physicians, specialists and health policy makers.

more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Induction of humoural and cellular immunity by immunisation with HCV particle vaccine in a non-human primate model

Induction of humoural and cellular immunity by immunisation with HCV particle vaccine in a non-human primate model | Hepatitis C New Drugs Review | Scoop.it
Objective Although HCV is a major cause of chronic liver disease worldwide, there is currently no prophylactic vaccine for this virus. Thus, the development of an HCV vaccine that can induce both humoural and cellular immunity is urgently needed. To create an effective HCV vaccine, we evaluated neutralising antibody induction and cellular immune responses following the immunisation of a non-human primate model with cell culture-generated HCV (HCVcc).

Design To accomplish this, 10 common marmosets were immunised with purified, inactivated HCVcc in combination with two different adjuvants: the classically used aluminum hydroxide (Alum) and the recently established adjuvant: CpG oligodeoxynucleotide (ODN) wrapped by schizophyllan (K3-SPG).

Results The coadministration of HCVcc with K3-SPG efficiently induced immune responses against HCV, as demonstrated by the production of antibodies with specific neutralising activity against chimaeric HCVcc with structural proteins from multiple HCV genotypes (1a, 1b, 2a and 3a). The induction of cellular immunity was also demonstrated by the production of interferon-γ mRNA in spleen cells following stimulation with the HCV core protein. These changes were not observed following immunisation with HCVcc/Alum preparation. No vaccination-related abnormalities were detected in any of the immunised animals.

Conclusions The current preclinical study demonstrated that a vaccine included both HCVcc and K3-SPG induced humoural and cellular immunity in marmosets. Vaccination with this combination resulted in the production of antibodies exhibiting cross-neutralising activity against multiple HCV genotypes. Based on these findings, the vaccine created in this study represents a promising, potent and safe prophylactic option against HCV.
more...
No comment yet.